Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has issued an update.
QIAGEN N.V. announced a managerial transaction involving Elaine Mardis, a member of its administrative body, which included the release and grant of Restricted Stock Units (RSUs). The transaction highlights the company’s ongoing commitment to aligning managerial interests with shareholder value, potentially impacting its market perception and stakeholder confidence.
More about Qiagen
QIAGEN N.V. is a prominent player in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its innovative solutions that enable customers to gain valuable insights from biological samples.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.